Next Article in Journal
The Risk of Venipuncture in Newborn with Severe Hemophilia: Case Report of a Large Elbow Hemorrhage and Literature Review of Compartment Syndrome
Previous Article in Journal
Successful Use of Phlebotomy to Treat Severe Secondary Polycythemia Due to Chronic Lung Disease
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 13
Issue 2
10.4081/hr.2021.9080
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients

by
Elisa Lucchini
1,
Chiara Rusconi
2,
Mario Levis
3,
Francesca Ricci
4,
Armando Santoro
4,
Umberto Ricardi
3,
Stefano Volpetti
5,
Fabio Matrone
6,
Anna di Russo
7,
Manuela Caizzi
1,
Anna Schiattarella
8 and
Francesco Zaja
1,2,3,4,5,6,7,8,9,*
1
Department of Hematology, Azienda Sanitaria Universitaria Giuliano- Isontina, 34125 Trieste, Italy
2
Division of Hematology and Stem Cell Transplantation Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy
3
Department of Oncology, University of Torino, 10125 Torino, Italy
4
Department of Oncology and Hematology, Humanitas Clinical and Research Center—IRCCS, Rozzano, 20133 Milano, Italy
5
Department of Hematology, Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy
6
Department of Radiation Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33170 Pordenone, Italy
7
Division of Radiotherapy Oncology Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy
8
Department of Radiotherapy, Azienda Sanitaria Universitaria Giuliano-Isontina, 34151 Trieste, Italy
9
Department of Medical, Surgical and Health Sciences, University of Trieste, SC Ematologia—Ospedale Maggiore, Piazza dell’Ospitale 1, 34125 Trieste, Italy
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2021, 13(2), 9080; https://doi.org/10.4081/hr.2021.9080
Submission received: 23 January 2021 / Revised: 10 April 2021 / Accepted: 30 April 2021 / Published: 9 June 2021

Abstract

The rate of complete remission (CR) with the anti-PD1 immune checkpoint inhibitors (ICI) nivolumab (N) and pembrolizumab (P) in patients with relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) is low (20–30%), and the majority of patients eventually relapse. One strategy to improve their outcome is to combine ICI with radiotherapy (ICI-RT), taking advantage of a supposed synergistic effect. We retrospectively collected data of 12 adult patients with R/R cHL treated with ICI-RT delivered during or within 8 weeks from the start or after the end of ICI. Median age at ICI-RT was 37 years, 50% had previously received an autologous stem cell transplantation (SCT) and 92% brentuximab vedotin. RT was given concurrently, before or after ICI in 4, 1 and 7 patients. Median RT dose was 30 Gy, for a median duration of 22 days. Median number of ICI administrations was 15. Overall response and CR rate were 100% and 58%. Nine patients received subsequent SCT consolidation (7 allogeneic and 2 autologous). After a median follow-up of 18 months, 92% of patients were in CR. No major concerns about safety were reported. ICI-RT combination appears to be a feasible and highly active bridge treatment to transplant consolidation.
Keywords: nivolumab; pembrolizumab; radiotherapy; hodgkin lymphoma; ICI-RT nivolumab; pembrolizumab; radiotherapy; hodgkin lymphoma; ICI-RT

Share and Cite

MDPI and ACS Style

Lucchini, E.; Rusconi, C.; Levis, M.; Ricci, F.; Santoro, A.; Ricardi, U.; Volpetti, S.; Matrone, F.; di Russo, A.; Caizzi, M.; et al. Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients. Hematol. Rep. 2021, 13, 9080. https://doi.org/10.4081/hr.2021.9080

AMA Style

Lucchini E, Rusconi C, Levis M, Ricci F, Santoro A, Ricardi U, Volpetti S, Matrone F, di Russo A, Caizzi M, et al. Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients. Hematology Reports. 2021; 13(2):9080. https://doi.org/10.4081/hr.2021.9080

Chicago/Turabian Style

Lucchini, Elisa, Chiara Rusconi, Mario Levis, Francesca Ricci, Armando Santoro, Umberto Ricardi, Stefano Volpetti, Fabio Matrone, Anna di Russo, Manuela Caizzi, and et al. 2021. "Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients" Hematology Reports 13, no. 2: 9080. https://doi.org/10.4081/hr.2021.9080

APA Style

Lucchini, E., Rusconi, C., Levis, M., Ricci, F., Santoro, A., Ricardi, U., Volpetti, S., Matrone, F., di Russo, A., Caizzi, M., Schiattarella, A., & Zaja, F. (2021). Immune Checkpoint Inhibitors in Combination with Radiotherapy as Salvage Treatment for Relapsed/Refractory Classical Hodgkin Lymphoma: A retrospective Analysis in 12 Patients. Hematology Reports, 13(2), 9080. https://doi.org/10.4081/hr.2021.9080

Article Metrics

Back to TopTop